- hospitalization at study inclusion - weight <50 kg - acute myocardial infarction - severe heart failure, characterized as nyha class 3 or 4 - use of concomitant medications that prolong the qt/qtc interval. - qtc >450ms - bilirubin ≥ 1,5 x unl, (except for known m. meulengracht) - ast/alt ≥ 3 x uln - albumine ≤ 2.8 g/dl - hemoglobin ≤ 9 g/dl - leucocytes ≤ 2000/µl - neutrophiles ≤ 1000/µl - thrombocytes ≤ 100.000/µl - troponin elevation - bnp > 500 pg/ml - creatine kinase > 5 x uln - creatinine >1,5 mg/dl - uncorrected hypopotassemia or hypomagnesemia - history of hypoglycemic events - history of or present cardial arrhythmia (except atrial fibrillation or paroxysmal supraventricular tachycardia) - bradycardia < 60 beats/min - history of retinopathy or maculopathy - psoriasis - myasthenia gravis - epilepsy - immunodeficiency syndromes or need for highly immunosuppressive medication - pre-existing medication with hydroxychloroquine - known g6pd deficiency. - participation in another interventional study - known hypersensibility to hydroxychloroquine and its derivates

- hospitalization at study inclusion - weight <50 kg - acute myocardial infarction - severe heart failure, characterized as nyha class 3 or 4 - use of concomitant medications that prolong the qt/qtc interval. - qtc >450ms - bilirubin ≥ 1,5 x unl, (except for known m. meulengracht) - ast/alt ≥ 3 x uln - albumine ≤ 2.8 g/dl - hemoglobin ≤ 9 g/dl - leucocytes ≤ 2000/µl - neutrophiles ≤ 1000/µl - thrombocytes ≤ 100.000/µl - troponin elevation - bnp > 500 pg/ml - creatine kinase > 5 x uln - creatinine >1,5 mg/dl - uncorrected hypopotassemia or hypomagnesemia - history of hypoglycemic events - history of or present cardial arrhythmia (except atrial fibrillation or paroxysmal supraventricular tachycardia) - bradycardia < 60 beats/min - history of retinopathy or maculopathy - psoriasis - myasthenia gravis - epilepsy - immunodeficiency syndromes or need for highly immunosuppressive medication - pre-existing medication with hydroxychloroquine - known g6pd deficiency. - participation in another interventional study - known hypersensibility to hydroxychloroquine and its derivates